Type: All cancers
We are pleased to announce the recipient of the 2025 Sally Crossing AM Award, Professor Keall, who leads the Image X Institute at the University of Sydney, for engaging consumers throughout his research which has positively impacted the lives of millions of cancer patients.
Dr Cohen and his team have identified two small-molecule drugs that inhibit the action of telomerase, and this project aims to advance the efficacy and safety of these drugs.
Dr van Delft and Dr Lew co-lead a team with Dr White that aims to enhance the effectiveness of venetoclax, rendering resistant cancer cells sensitive to treatment.
The project aims to develop experimental research using the proposed hardware to show 3D imagining during treatment, MRI quality imaging during treatment and reconstructing actual delivered dose post treatment.
Dr Mithraprabhu and her team aims to overcome the challenges caused by the genetic complexity of multiple myeloma by using DNA obtained from the blood instead of a single-site bone marrow biopsy.
Associate Professor MacKenzie and her team will define specific drug targets and develop diagnostic methods for therapeutic application in cancers that relay on a specific telomere maintenance mechanism referred to as Alternative Lengthening of Telomeres (ALT).
Dr Klaartje Somers from Children’s Cancer Institute and Dr Deborah Meyran from Peter MacCallum Cancer Centre, along with their teams, are investigating ways to overcome the challenges of treating solid tumours with CAR T-cell immunotherapy
A/Prof Swarbrick and his team will study multiple solid cancers that have a range of responses to immunotherapy. The team will identify which types of stromal cells block immune responses to cancer and how they do this.
Prof Price is investigating how new imaging technology could be used to enhance radiotherapy effectiveness in solid cancers.